Antimicrobial resistance is one of the most pressing public health threats of our time, with the World Health Organization warning that a growing number of infections are becoming harder to treat as existing drugs lose their effectiveness. In this context, the emergence of new classes of antibiotics is critical. Lakewood-Amedex Biotherapeutics Inc. (NASDAQ: LABT), a clinical-stage biotechnology company based in Sarasota, Florida, is developing a novel class of antimicrobials called Bisphosphocins, which offer a promising approach to combating resistant bacteria. The company's lead candidate, Nu-3, is a topical gel formulation targeting infected diabetic foot ulcers, a condition that affects millions worldwide.
On August 25, 2026, B2i Digital, Inc. announced that it has welcomed Lakewood-Amedex as its newest Featured Company. This partnership aims to increase visibility for Lakewood-Amedex among retail and institutional investors, particularly as the company prepares to initiate a Phase 2a clinical trial for Nu-3. The trial will evaluate the safety and efficacy of Nu-3 gel at three concentrations (2%, 5%, and 10%) in patients with infected diabetic foot ulcers, with the goal of advancing the candidate to a larger Phase 2b study.
The Bisphosphocin class represents a departure from traditional antibiotics. Instead of interfering with bacterial metabolic pathways, these compounds disrupt the bacterial cell membrane physically, leading to rapid bacterial death. This mechanism is believed to make it difficult for bacteria to develop resistance. In laboratory studies, Nu-3 has demonstrated a high barrier to resistance, and it has shown broad-spectrum activity against a range of resistant pathogens, including MRSA.
Diabetic foot ulcers are a significant complication of diabetes, affecting a substantial portion of the 830 million people living with the disease globally. Approximately one-third of these individuals will develop a foot ulcer, and about half of these ulcers become infected. In 15% to 20% of infected cases, resistant pathogens such as MRSA are involved, making treatment even more challenging. The potential impact of an effective topical antimicrobial like Nu-3 is therefore considerable.
Lakewood-Amedex has reported a robust preclinical package supporting the advancement of Nu-3. In July 2026, the company announced that Nu-3 was well tolerated in an FDA-required safety study at dose levels significantly higher than those planned for the Phase 2a trial, with very low systemic exposure and no inhibition of wound healing. These findings support the selection of doses for the upcoming trial.
In addition, the company has secured a strong intellectual property estate, with 72 issued patents and 29 pending applications covering the Bisphosphocin class, formulations of Nu-3, and related processes. The principal patents extend through 2038, with recent applications running through 2044, providing long-term protection for the platform.
Lakewood-Amedex began trading on the Nasdaq Capital Market under the ticker symbol LABT following a direct listing in April 2026. The company is led by CEO Kelvin Cooper, Ph.D., who emphasized the importance of the B2i Digital partnership in communicating the science and milestones to a broader investor audience.
B2i Digital, headquartered in New York City, offers a range of services to public companies, including featured company profiles, conference partnerships, and access to its extensive media network. The company's platform reaches over 330 million combined monthly audience across 800+ news outlets and has a substantial social media following. The full profile of Lakewood-Amedex is expected to be available soon on B2i Digital's website at B2i Digital Featured Companies.
David Shapiro, CEO of B2i Digital, highlighted the significance of Lakewood-Amedex's work: "Antimicrobial resistance keeps narrowing the list of drugs that still work against all pathogens, and the compounds coming to replace them are mostly variations on mechanisms that bacteria have already learned to defeat. Lakewood-Amedex has spent years on a compound class that disrupts the bacterial membrane physically, and in laboratory work Nu-3 has demonstrated a high barrier to resistance. The company is preparing a Phase 2a trial in infected diabetic foot ulcers with one of the field’s most respected clinicians as study chair, which makes this a company investors should meet early."
The Phase 2a study will be chaired by David G. Armstrong, DPM, M.D., Ph.D., Distinguished Professor of Surgery and Neurological Surgery at the Keck School of Medicine of USC, who also serves as a Scientific Advisor for the program. His involvement adds credibility to the trial design and execution.
As Lakewood-Amedex moves toward the initiation of its Phase 2a trial, the partnership with B2i Digital is expected to raise awareness of the Bisphosphocin platform and its potential to address a significant unmet medical need. For investors, the company represents a unique opportunity to participate in the development of a novel class of antimicrobials that could play a crucial role in the fight against antibiotic resistance.
